Table 1.
Antimicrobial susceptibility results of three clinical Klebsiella pneumoniae isolates and their E. coli transconjugants and transformants.
| Strain | MICs (mg/l) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IPMa | MEM | ETP | CAZ | CTX | TZP | SCF | CZA | FEP | ATM | CMZ | CIP | AK | TET | COL | TGC | |
| K. pneumoniae KP-426 | 64 | 128 | 128 | >128 | >128 | 256/4 | 256/128 | ≤0.5/4 | >128 | >128 | >128 | >32 | >128 | >128 | 1 | 4 |
| K. pneumoniae KP-C76 | 64 | 128 | >128 | >128 | >128 | 256/4 | 256/128 | ≤0.5/4 | >128 | >128 | >128 | >32 | >128 | >128 | 4 | 4 |
| K. pneumoniae KP-CT77 | 64 | 64 | 128 | 128 | 128 | 256/4 | 128/64 | 1/4 | >128 | >128 | 128 | >32 | >128 | >128 | 8 | 32 |
| E. coli EC600 | ≤0.5 | ≤0.5 | ≤0.5 | ≤0.5 | ≤0.5 | ≤4/4 | ≤1/0.5 | ≤0.5/4 | ≤0.5 | ≤0.5 | 1 | ≤0.25 | ≤4 | 0.5 | 1 | 0.125 |
| E. coli EC600 transconjugant of KP-426 | ≤0.5 | ≤0.5 | ≤0.5 | ≤0.5 | ≤0.5 | ≤4/4 | ≤1/0.5 | ≤0.5/4 | ≤0.5 | ≤0.5 | 1 | ≤0.25 | ≤4 | 64 | 1 | 0.25 |
| E. coli EC600 transconjugant of KP-C76 | ≤0.5 | ≤0.5 | ≤0.5 | ≤0.5 | ≤0.5 | ≤4/4 | ≤1/0.5 | ≤0.5/4 | ≤0.5 | ≤0.5 | 1 | ≤0.25 | ≤4 | 64 | 1 | 0.25 |
| E. coli EC600 transconjugant of KP-CT77 | ≤0.5 | ≤0.5 | ≤0.5 | ≤0.5 | ≤0.5 | ≤4/4 | ≤1/0.5 | ≤0.5/4 | ≤0.5 | ≤0.5 | 1 | ≤0.25 | ≤4 | 128 | 1 | 1 |
| E. coli DH5α | ≤0.5 | ≤0.5 | ≤0.5 | ≤0.5 | ≤0.5 | ≤4/4 | ≤1/0.5 | ≤0.5/4 | ≤0.5 | ≤0.5 | ≤0.5 | ≤0.25 | ≤4 | 0.5 | 0.5 | 0.125 |
| E. coli DH5α/pUC18 | ≤0.5 | ≤0.5 | ≤0.5 | ≤0.5 | ≤0.5 | ≤4/4 | ≤1/0.5 | ≤0.5/4 | ≤0.5 | ≤0.5 | ≤0.5 | ≤0.25 | ≤4 | 0.5 | 0.5 | 0.125 |
| E. coli DH5α/pUC18-tet(A) | ≤0.5 | ≤0.5 | ≤0.5 | ≤0.5 | ≤0.5 | ≤4/4 | ≤1/0.5 | ≤0.5/4 | ≤0.5 | ≤0.5 | ≤0.5 | ≤0.25 | ≤4 | 64 | 0.5 | 0.25 |
| E. coli DH5α/pUC18-tet(A)-G300E | ≤0.5 | ≤0.5 | ≤0.5 | ≤0.5 | ≤0.5 | ≤4/4 | ≤1/0.5 | ≤0.5/4 | ≤0.5 | ≤0.5 | ≤0.5 | ≤0.25 | ≤4 | 128 | 0.5 | 1 |
a
IPM, imipenem; MEM, meropenem; ETP, ertapenem; CAZ, ceftazidime; CTX, cefotaxime; TZP, piperacillin/tazobactam; SCF, cefoperazone/sulbactam; CZA, ceftazidime/avibactam; FEP, cefepime; ATM, aztreonam; CMZ, cefmetazole; CIP, ciprofloxacin; AK, amikacin; TET, tetracycline; COL, colistin; and TGC, tigecycline. For piperacillin/tazobactam and ceftazidime/avibactam, the tazobactam and avibactam were tested at a fixed concentration of 4mg/l. For cefoperazone/sulbactam, the combination was tested with concentrations of 2:1 ratio (antibiotic: inhibitor).